Citi raised the firm’s price target on Beam Therapeutics (BEAM) to $64 from $56 and keeps a Buy rating on the shares. With positive BEAM-302 ...

The Cambridge-based company touted the data as evidence of the first successful use of CRISPR gene editing to fix a ...

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has ...

Beam Therapeutics Inc. BEAM announced positive initial safety and efficacy data from a phase I/II study, which is evaluating ...

Beam Therapeutics (NASDAQ:BEAM – Get Free Report)‘s stock had its “buy” rating reissued by research analysts at HC Wainwright ...

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Roche Holding AG (RHHVF – Research Report) ...

Beam Therapeutics Inc. (NASDAQ:BEAM – Get Free Report) has been given an average recommendation of “Buy” by the fourteen research firms that are covering the company, Marketbeat Ratings reports. Two ...

The one-time therapy appears to correct the mutation that causes the disease, known as Alpha-1 antitrypsin deficiency (AATD), ...

Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, ...

BEAM-302 "has set the bar for efficacy in this space," William Blair analysts wrote in an investor note on Monday.

The small study in patients with a rare disorder that causes liver and lung damage showed the potential for precisely ...

A Beam Therapeutics gene-editing therapy designed to fix a mutation at the root of a rare liver protein deficiency now has early signs of efficacy along with safety data that ease some concerns ...